SI-BONE, Inc. (SIBN)

US — Healthcare Sector
Peers: NUVA  CNMD  KIDS  LUNG  IRMD  OFIX  NPCE  ITGR  SGHT  RPID  TCMD  RXST  AXGN  TMCI  ESTA 

Automate Your Wheel Strategy on SIBN

With Tiblio's Option Bot, you can configure your own wheel strategy including SIBN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SIBN
  • Rev/Share 4.1713
  • Book/Share 3.9507
  • PB 4.8042
  • Debt/Equity 0.2221
  • CurrentRatio 8.5255
  • ROIC -0.1501

 

  • MktCap 808823210.0
  • FreeCF/Share -0.4783
  • PFCF -39.9379
  • PE -30.265
  • Debt/Assets 0.1635
  • DivYield 0
  • ROE -0.16

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
SIBN
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?
SIBN
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read More
image for news What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet
SIBN
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 41.2% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet
SI-BONE, Inc. (SIBN) Q1 2025 Earnings Call Transcript
SIBN
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral

SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Saqib Iqbal - VP, FP&A, Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America David Turkaly - Citizens JMP Young Li - Jefferies Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Operator Good afternoon. And welcome to SI-BONE's First Quarter 2025 Earnings Conference Call.

Read More
image for news SI-BONE, Inc. (SIBN) Q1 2025 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript
SIBN
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral

SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript

Read More
image for news SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?
SIBN
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?

About SI-BONE, Inc. (SIBN)

  • IPO Date 2018-10-17
  • Website https://si-bone.com
  • Industry Medical - Devices
  • CEO Ms. Laura A. Francis MBA
  • Employees 349

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.